Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib in metastatic thyroid cancer
NCT00094055Phase 2Completed
- Sponsor
- Pfizer
- Start
- Sep 2004
- Primary completion
- Jan 2009
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axitinib in thyroid cancer, sponsored by Pfizer. Primary endpoint: Objective Response at 206 weeks. Started Sep 2004; status: completed.
02
Drugs
axitinib
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT00094055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00094055.